Lucy Scientific Discovery (Lucy Scientific Discovery) ROCE % : -194.21% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lucy Scientific Discovery's annualized ROCE % for the quarter that ended in Dec. 2023 was -194.21%.

Lucy Scientific Discovery ROCE % Historical Data

The historical data trend for Lucy Scientific Discovery's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery ROCE % Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

ROCE %

-303.33

-287.14

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial						-	-854.58	-129.84	-127.17	-194.21

Lucy Scientific Discovery ROCE % Calculation

Lucy Scientific Discovery's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-7.022	/	( ( (4.632 - 5.81)	+	(8.779 - 2.71) )	/ 2 )
	=	-7.022	/	( (-1.178	+	6.069)	/ 2 )
	=	-7.022	/	2.4455
	=	-287.14 %

Lucy Scientific Discovery's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-4.7	/	( ( (6.266 - 2.226)	+	(4.287 - 3.487) )	/ 2 )
	=	-4.7	/	( ( 4.04	+	0.8 )	/ 2 )
	=	-4.7	/	2.42
	=	-194.21 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Lucy Scientific Discovery (NAS:LSDI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lucy Scientific Discovery ROCE % Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website

https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.

Executives

Richard D Nanula	director, officer: Executive Chairman	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko	officer: Chief Financial Officer	C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany	director, officer: President and CEO	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy	officer: Chief Scientific Officer	C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6